antihypertensive that stimulates adrenergic alpha 2 receptors in CNS

-used in withdrawal symptoms from opiates

blocks pump in neuron allowing dopamine and NE into vesicles

-has high lipid solubility so has CNS effects including depression

pumped into presynaptic cleft and into vesicles

-depletes NE in vesicles

-also indirect sympathomimetic initially

-anti-hypertensive

-causes hypotension, diarrhea,

-No CNS effects (too polar)

competitive inhibitor of tyrosine hydroxylase

-treats pheochromocytoma by decreasing catecholamine synthesis by the tumor

stimulates beta-1, beta-2, and alpha

-uses: hypersensitivity, cardiac arrest, adjunct to local anesthetic

stimulates alpha-1 and beta-1

-can be used for shock but dopamine is better

pure beta agonist

-can be used for asthma but will cause myocardial stimulation

treatment of shock

-dopamine receptors cause renal vasodilation

-higher dose beta-1 (increase HR)

-even higher, alpha (increase TPR)

pure alpha agonist

-COMT can't metab, increased t1/2

pure alpha agonist

-COMT can't metab, increased t1/2

pure alpha agonist

-COMT can't metab, increased t1/2

-commonly used in nasal sprays

indirect symphathomimetic

-not metab by MAO

indirect symphathomimetic

-not metab by MAO

selective beta-2 agonist

-bronchodilator

selective beta-2 agonist

-bronchodilator

selective beta-2 agonist

-bronchodilator

beta-2 agonist

-prevent premature parturition

selective beta-1 agonist

-CHF

irreversible apha antagonist

selective alpha-1 competetive antagonists

-effective with BPH

prototype beta blocker

-membrane-stabilizing ability

-beta blocker

-treatment of glaucoma

beta blocker

-cardioselective

beta blocker

-cardioselective

beta blocker

-partial agonist (intrinsic sympathomimetic ability)

-supposedly good for asthmatics

beta blocker

-very short t1/2

-therefore good in deciding if beta-blocker therapy in MI will be beneficial

muscarinic selective

-treatment of GI hypomotility

-increased t1/2 (not sensitive to AChE)

(Benadryl)

-antihistamine that can block muscarinic receptors

anti-muscarinic

-oxygen bridge allows for CNS penetration

-used for motion sickness

anti-muscarinic

-used for athma, COPD

-quaternary amine (unable to cross BBB due to fixed charge)

antimuscarinic

-largely used for preanesthetic use

competitive antagonist that inhibits AChE

-short duration (test for myasthenia gravis)

inhibits AChE

-carbamate

inhibits AChE

-carbamate

inhibits AChE

-carbamate

irreversible inhibits AChE

-organophosphate

-used for insecticides (parathion, malathion)

Pralidoxime

(2-PAM)

-used for antidote for organophosphate poisoning

-with atropine

-barbiturate

-effective treatment in grand mal and simple partial seizures

-exacerbates petit mal seizures

(mephobarbital, metharbital)

-deoxy barbiturate

-similar to phenobarbital (seizures)

-benzodiazepine

-treatment in status epilepticus (quick acting)

-enhances GABA

-also used as a spasmolytic drug

-benzodiazepine

-treatment in status epilepticus (quick acting)

-enhances GABA

-benzodiazepine

-long acting, efficacious against petit mal seizures

(divalproex sodium)

very commonly used in seizures

-hepatotoxicity

limits spread of seizures

-non-first order pharmacokinetics

-prolongs Na inactivation

-increases release of GABA

-used mainly to treat chronic pain of neural origin

-Alzheimer's drug

-antagonist at glutamate's NMDA receptor

Alzheimer's drug

cholinesterase inhibitor

(Aricept)

Alzheimer's drug

cholinesterase inhibitor

Alzheimer's drug

cholinesterase inhibitor

treats Parkinson's Disease

-almost always in combination with carbidopa

(Sinemet)

-decreases excessive influence of Enkephalin pathway

-AAADC to dopamine after crossing BBB

-COMT to O-methyl dopa (blocks transport into CNS)

-psychosis, n/v, arrhythmias

antiviral agent that appears to work by increasing dopamine output or nigrostriatal neurons

-tolerance can occur

antimuscarinic used with older antipsychotics

MAO-B inhibitor

-inhibits MAO resonsible for degrading dopamine without dangerous effects of non-specific MAO inhibitor

dopamine agonist

-have efficacy in late Parkinson's (not dependent upon intact nigrostriatal neurons)

dopamine agonist

-have efficacy in late Parkinson's (not dependent upon intact nigrostriatal neurons)

dopamine agonist

-have efficacy in late Parkinson's (not dependent upon intact nigrostriatal neurons)

COMT inhibitor

-reduces O-methyl dopa formation

-old antipsychotic

-blocks dopamine

-sedation, hypotension

-antimuscarinic -> fewer movement problems

-old antipsychotic

-blocks dopamine

-also used for hospital agitation

-not antimuscarinic ->movement trouble

-depository injection

-old antipsychotic

-blocks dopamine

-also used for hospital agitation

-not antimuscarinic ->movement trouble

-depository injection

-new antipsychotic

-blocks 5-HT, all DA receptors, but only mild D2 block

-no extrapyramidal symptoms

-produces agranulocytosis

-must monitor WBC

-new antipsychotic

-only mild blockade at D2

-acts like clozapine but no agranulocytosis

-one of the main current antipsychotics

-new antipsychotic

-only mild blockade at D2

-acts like clozapine but no agranulocytosis

-one of the main current antipsychotics

-new antipsychotic

-only mild blockade at D2

-acts like clozapine but no agranulocytosis

-one of the main current antipsychotics

-new antipsychotic

-only mild blockade at D2

-acts like clozapine but no agranulocytosis

-one of the main current antipsychotics

-anti-psychotic

-D2 partial agonist (DA stabilizer)

-minimal sedation and hypotensive effects

-spasmolytic

-GABA agonist

-sedation

-spasmolytic

-blocks release of Ca from skeletal sarcoplasmic reticulum

-muscle weakness

-spasmolytic

-sedation

-spasmolytic

-sedation